Table 1 Summary of PRL3 expression across different tumor types
From: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
Tumor type | PRL3+ | PRL3− | Total | % PRL3+ |
|---|---|---|---|---|
Liver | 16 | 4 | 20 | 80 |
Lung | 9 | 1 | 10 | 90 |
Colon | 7 | 3 | 10 | 70 |
Breast | 9 | 1 | 10 | 90 |
Stomach | 12 | 2 | 14 | 86 |
Thyroid | 11 | 1 | 12 | 92 |
Pancreas | 6 | 1 | 7 | 86 |
Kidney | 13 | 5 | 18 | 72 |
AML | 6 | 6 | 12 | 50 |
Bladder | 24 | 10 | 34 | 71 |
Prostate | 4 | 0 | 4 | 100 |
Total | 117 | 34 | 151 | |
Average | 80.6 |
